ロード中...
Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting. This study used a partitioned survival model, with three discrete health states (progression-free survival, post-...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6964893/ https://ncbi.nlm.nih.gov/pubmed/31945065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0226196 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|